Company intelligence / Profile preview
Medistem Panama
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
Overview
Medistem Panama has developed proprietary methods to isolate and expand highly potent mesenchymal stem cells ("Golden Cells™") from various sources. These are used in IRB-approved clinical trials targeting autoimmune and degenerative diseases such as multiple sclerosis, rheumatoid arthritis, osteoarthritis—with future plans for spinal cord injury, autism spectrum disorder and cerebral palsy. The company’s research has led to dozens of scientific publications and numerous pending patents. Clinical results have shown promising outcomes in treated patients with chronic conditions.
- Therapeutic areas
- RheumatologyPsychiatryImmunologyNeurology
- Modalities
- Stem cell therapyCell therapy (specifically mesenchymal stem cells)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Medistem Panama.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medistem Panama.